FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045756872> ?p ?o ?g. }

• W2045756872 endingPage "745" @default.
• W2045756872 startingPage "739" @default.
• W2045756872 abstract "The notch pathway is overexpressed in pancreatic adenocarcinoma. RO4929097, an oral inhibitor of the γ-secretase enzyme has been safely given as a single agent in patients with advanced solid tumors. We aimed to evaluate the efficacy of RO4929097 in patients with pancreatic adenocarcinoma (PDA).A two-stage, single-arm Phase II trial was conducted in patients with previously treated metastatic PDA. RO4929097 was administered at a dose of 20 mg daily on days 1-3, 8-10 and 15-17 of 21-day cycles. The primary endpoint was survival at 6 months. Secondary endpoints included overall survival (OS), response rate, toxicities, pharmacokinetic and pharmacodynamic analyses.Eighteen patients were recruited, 17 in the first stage and one in the 2nd stage. It was decided to stop further enrollment after RO4929097 was discontinued by the sponsor and was no longer a development candidate. Three (25 %) of 12 evaluable patients achieved stable disease. The 6-month survival rate was 27.8 % (95 % CI 9.7-53.5). The median OS was 4.1 months (95 % CI 2.7-5.8 months) and median progression-free survival was 1.5 months (95 % CI 1.3-1.6 months). Pharmacokinetic properties of RO4929097 in patients (n = 5) with PDA was similar to that previously reported in other patient populations. There was a trend towards a decrease in HeyL (p = 0.08) gene expression in three patients following study drug administration.RO4929097 was well-tolerated in patients with previously treated PDA. Development of RO4929097 has been discontinued, but development of other notch-targeting agents in pancreatic cancer is continuing." @default.
• W2045756872 created "2016-06-24" @default.
• W2045756872 creator A5013199198 @default.
• W2045756872 creator A5015341987 @default.
• W2045756872 creator A5016574266 @default.
• W2045756872 creator A5031382329 @default.
• W2045756872 creator A5033720986 @default.
• W2045756872 creator A5048073439 @default.
• W2045756872 creator A5067509440 @default.
• W2045756872 creator A5078259926 @default.
• W2045756872 creator A5086504706 @default.
• W2045756872 date "2014-03-27" @default.
• W2045756872 modified "2023-09-30" @default.
• W2045756872 title "A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma" @default.
• W2045756872 cites W1931508686 @default.
• W2045756872 cites W1968818485 @default.
• W2045756872 cites W1976371429 @default.
• W2045756872 cites W1977075884 @default.
• W2045756872 cites W1986829345 @default.
• W2045756872 cites W1990893332 @default.
• W2045756872 cites W2013709636 @default.
• W2045756872 cites W2019607817 @default.
• W2045756872 cites W2026794550 @default.
• W2045756872 cites W2056768114 @default.
• W2045756872 cites W2066135299 @default.
• W2045756872 cites W2106261547 @default.
• W2045756872 cites W2126959323 @default.
• W2045756872 cites W2135201496 @default.
• W2045756872 cites W2146952185 @default.
• W2045756872 cites W2148054025 @default.
• W2045756872 cites W2151253787 @default.
• W2045756872 cites W2165480504 @default.
• W2045756872 cites W2170785598 @default.
• W2045756872 doi "https://doi.org/10.1007/s10637-014-0083-8" @default.
• W2045756872 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4292847" @default.
• W2045756872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24668033" @default.
• W2045756872 hasPublicationYear "2014" @default.
• W2045756872 type Work @default.
• W2045756872 sameAs 2045756872 @default.
• W2045756872 citedByCount "90" @default.
• W2045756872 countsByYear W20457568722014 @default.
• W2045756872 countsByYear W20457568722015 @default.
• W2045756872 countsByYear W20457568722016 @default.
• W2045756872 countsByYear W20457568722017 @default.
• W2045756872 countsByYear W20457568722018 @default.
• W2045756872 countsByYear W20457568722019 @default.
• W2045756872 countsByYear W20457568722020 @default.
• W2045756872 countsByYear W20457568722021 @default.
• W2045756872 countsByYear W20457568722022 @default.
• W2045756872 countsByYear W20457568722023 @default.
• W2045756872 crossrefType "journal-article" @default.
• W2045756872 hasAuthorship W2045756872A5013199198 @default.
• W2045756872 hasAuthorship W2045756872A5015341987 @default.
• W2045756872 hasAuthorship W2045756872A5016574266 @default.
• W2045756872 hasAuthorship W2045756872A5031382329 @default.
• W2045756872 hasAuthorship W2045756872A5033720986 @default.
• W2045756872 hasAuthorship W2045756872A5048073439 @default.
• W2045756872 hasAuthorship W2045756872A5067509440 @default.
• W2045756872 hasAuthorship W2045756872A5078259926 @default.
• W2045756872 hasAuthorship W2045756872A5086504706 @default.
• W2045756872 hasBestOaLocation W20457568722 @default.
• W2045756872 hasConcept C111113717 @default.
• W2045756872 hasConcept C112705442 @default.
• W2045756872 hasConcept C121608353 @default.
• W2045756872 hasConcept C126322002 @default.
• W2045756872 hasConcept C141071460 @default.
• W2045756872 hasConcept C143998085 @default.
• W2045756872 hasConcept C146357865 @default.
• W2045756872 hasConcept C151730666 @default.
• W2045756872 hasConcept C203092338 @default.
• W2045756872 hasConcept C2781182431 @default.
• W2045756872 hasConcept C31760486 @default.
• W2045756872 hasConcept C535046627 @default.
• W2045756872 hasConcept C71924100 @default.
• W2045756872 hasConcept C86803240 @default.
• W2045756872 hasConcept C90924648 @default.
• W2045756872 hasConceptScore W2045756872C111113717 @default.
• W2045756872 hasConceptScore W2045756872C112705442 @default.
• W2045756872 hasConceptScore W2045756872C121608353 @default.
• W2045756872 hasConceptScore W2045756872C126322002 @default.
• W2045756872 hasConceptScore W2045756872C141071460 @default.
• W2045756872 hasConceptScore W2045756872C143998085 @default.
• W2045756872 hasConceptScore W2045756872C146357865 @default.
• W2045756872 hasConceptScore W2045756872C151730666 @default.
• W2045756872 hasConceptScore W2045756872C203092338 @default.
• W2045756872 hasConceptScore W2045756872C2781182431 @default.
• W2045756872 hasConceptScore W2045756872C31760486 @default.
• W2045756872 hasConceptScore W2045756872C535046627 @default.
• W2045756872 hasConceptScore W2045756872C71924100 @default.
• W2045756872 hasConceptScore W2045756872C86803240 @default.
• W2045756872 hasConceptScore W2045756872C90924648 @default.
• W2045756872 hasIssue "4" @default.
• W2045756872 hasLocation W20457568721 @default.
• W2045756872 hasLocation W20457568722 @default.
• W2045756872 hasLocation W20457568723 @default.
• W2045756872 hasOpenAccess W2045756872 @default.
• W2045756872 hasPrimaryLocation W20457568721 @default.
• W2045756872 hasRelatedWork W1479708814 @default.

• next